BBIO ▲ +0.1% - BridgeBio Pharma, Inc. $BBIO - BridgeBio to Present New Data on the Impact of Oral Infigratinib on Medical Complications in Achondroplasia at the Annual ESPE Meeting 2026 BridgeBio Pharma rose 0.1% today following an announcement that the company will present new data on oral infigratinib's impact on medical complications in achondroplasia at the 2026 Annual ESPE Meeting. The presentation of clinical data on a lead program candidate could support investor confidence in the drug's development progress, though the modest price movement suggests the market has already priced in expectations around the program. 02-SEP-2026 07:30 AM ET